Skip to main content

Table 2 Hazard Ratio (HR) and 95% Confidence Interval (CI) of Disease-Specific Survival Following Initial GEP-NET Treatment, SEER-Medicare 1995–2010; Small Intestine Not Otherwise Specified: SI NOS; National Cancer Institute: NCI

From: Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients

Variable HR (95% CI)
Patient Volume
 low Ref
 medium 0.72 (0.57–0.91)
 high 0.62 (0.42–0.94)
Sex
 female Ref
 male 1.33 (1.07–1.65)
Age
 65–69 Ref
 70–74 1.29 (0.99–1.70)
 75–79 1.23 (0.93–1.63)
 80–84 1.24 (0.86–1.77)
 85–89 2.03 (1.35–3.07)
 90–94 2.10 (0.93–4.75)
Primary Site
 cecum Ref
 stomach 0.74 (0.49–1.11)
 duodenum 1.10 (0.55–2.25)
 jejunum/ileum 0.42 (0.27–0.65)
 SI NOS* 0.54 (0.33–0.90)
 appendix 0.73 (0.36–1.50)
 colon 1.00 (0.73–1.35)
 rectum 0.79 (0.56–1.12)
 pancreas 0.88 (0.54–1.43)
Treatment
 surgery Ref
 endoscopy 0.87 (0.51–1.47)
 chemotherapy 1.19 (0.81–1.75)
 radiation therapy 2.72 (1.70–4.35)
 somatostatin analogue 1.47 (1.04–2.10)
 surgery and endoscopy 0.85 (0.46–1.57)
 surgery and chemotherapy 0.91 (0.35–2.37)
 surgery and radiation therapy 1.84 (1.13–2.98)
 surgery, endoscopy, and chemotherapy 10.07 (6.91–14.674)
Comorbidity
 0 Ref
 1–2 1.31 (1.05–1.64)
 3+ 1.70 (1.24–2.34)
Differentiation
 well-differentiated Ref
 moderately-differentiated 1.81 (1.28–2.58)
 poorly-differentiated 3.82 (2.75–5.32)
Tumor Stage
 local Ref
 regional 1.76 (1.16–2.69)
 distant 5.61 (3.72–8.46)
Academic status
 no Ref
 yes 1.20 (0.97–1.48)
NCI status
 no Ref
 yes 0.49 (0.18–1.30)
  1. *Small Intestine Not Otherwise Specified: SI NOS; National Cancer Institute: NCI